Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Olema Pharmaceuticals, Inc. - Common Stock
(NQ:
OLMA
)
25.07
-0.57 (-2.22%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Olema Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 02, 2025
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference
November 21, 2025
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
November 20, 2025
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Announces Pricing of $190.0 Million Public Offering of Common Stock
November 19, 2025
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
November 18, 2025
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Third Quarter 2025 Financial and Operating Results
November 10, 2025
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 04, 2025
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology to Participate in Upcoming Investor Conferences
November 03, 2025
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025
October 30, 2025
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025
October 18, 2025
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2025
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 03, 2025
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer
September 02, 2025
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology to Participate in Upcoming Investor Conferences
August 20, 2025
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Second Quarter 2025 Financial and Operating Results
August 11, 2025
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2025
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2025
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 03, 2025
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting
May 28, 2025
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology to Participate in Upcoming Investor Conferences
May 21, 2025
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports First Quarter 2025 Financial and Operating Results
May 13, 2025
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology to Participate in Upcoming Investor Conferences
May 09, 2025
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2025
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025
April 25, 2025
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2025
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting
March 25, 2025
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
March 18, 2025
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 04, 2025
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference
February 19, 2025
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary
February 18, 2025
From
Olema Oncology
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
